- Race Oncology (RAC) flags the multi-billion-dollar market potential of its Zantrene drug as a potential cardio-protective agent and an anti-cancer agent
- The company says an independent analysis suggests a use case in nearly its entire target population if Zantene can demonstrate anti-cancer benefits
- If anti-cancer efficacy is demonstrated, Zantrene could peak at commercial values of US$1.7 billion in breast cancer alone in the US and US$3.4 billion worldwide
- Race says if additional indications are identified, revenue could increase to between US$5 billion and US$8 billion as the company expands
- RAC shares are up 7.12 per cent and trading at $1.88 at 12:23 pm AEST
Race Oncology (RAC) has released a detailed assessment of the market potential for its Zantrene drug to function as a cardio-protective agent and an anti-cancer agent for the treatment of breast, endometrial and ovarian cancers.
The blinded primary market research commissioned by Race and conducted by Triangle
Insights suggested that Zantrene could be widely adopted for nearly its entire identified breast cancer target population.
“It is pleasing to now be able to share this complete research report to further illustrate what the cardio-protection market potential may look like,” RAC CEO and Managing Director Damian Clarke-Bruce said.
“This has been defined with three unique clinical scenarios, where Zantrene has demonstrated pre-clinical and historically, early-phase therapeutic outcomes.”
In February, RAC received human ethics approval from the Hunter England Human Research Ethics Committee for the observational stage of a planned phase I-IIb clinical trial of Zantrene.
If anti-cancer efficacy is demonstrated, sales for Zantrene could peak at commercial values of US$1.7 billion (A$2.5 billion) in breast cancer alone within the US and US$3.4 billion worldwide.
Race said if additional indications were identified, revenue could increase to between US$5 billion and US$8 billion as the company expanded.
If anti-cancer data is not sufficiently detected, Zantrene could also be leveraged as a cardio-protective therapy, assuming no impact on the anti-cancer effect of the underlying anthracycline regimen.
Follow-up studies that demonstrated positive effects in the hearts of mice have led to additional preclinical studies in animal cell models to explore the mechanism of action and optimal therapeutic usage of Zantrene.
Zantrene is an anthracene-based anti-cancer agent, initially developed as a less cardio-toxic alternative to commonly used anthracycline chemotherapeutics such as doxorubicin.
RAC shares were up 7.12 per cent and trading at $1.88 at 12:23 pm AEST.